Details of the Drug Combination

General Information of Drug Combination (ID: DCHOZO2)

Drug Combination Name
Nintedanib CP-868596
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs Nintedanib   DMMQ2OW CP-868596   DMZIM37
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 23.168
Bliss Independence Score: 33.549
Loewe Additivity Score: 1.559
LHighest Single Agent (HSA) Score: 2.436

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Nintedanib
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [3]
Ovarian neoplasm N.A. Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Indication(s) of CP-868596
Disease Entry ICD 11 Status REF
Gastrointestinal cancer 2C11 Phase 3 [5]
Gastrointestinal stromal tumour 2B5B Phase 3 [6]
Acute myelogenous leukaemia 2A41 Phase 2 [7]
Acute myeloid leukaemia 2A60 Phase 2 [6]
Malignant glioma 2A00.0 Phase 1 [7]
CP-868596 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Modulator [8]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
3 Nintedanib FDA Label
4 ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7882).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.